

# AD-A235 540



## DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

This form is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and reviewing the collection of information, sending comments regarding this burden estimate or any other aspect of this collection of information, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Avenue, Washington, DC 20503, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

2. REPORT DATE  
1990

3. REPORT TYPE AND DATES COVERED  
Reprint

4. TITLE AND SUBTITLE  (see title on reprint)		5. FUNDING NUMBERS  Program Element No. NWED QAXM	
6. AUTHOR(S)  Brook et al.		Work Unit No. 4440-00129	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  Armed Forces Radiobiology Research Institute Defense Nuclear Agency Bethesda, MD 20889-5145		8. PERFORMING ORGANIZATION REPORT NUMBER  SR91-1	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)  Defense Nuclear Agency Washington, DC 20305		10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION/AVAILABILITY STATEMENT  Approved for public release; distribution unlimited.		12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) <div style="float: right; border: 1px solid black; padding: 5px; margin-top: 10px;">           DTIC COPY INSTRUMENT 6         </div> <div style="float: right; margin-top: 10px;">           Annotation For NTIS GRAB DTIC TAB Unannounced Justification  By Distribution Availability Codes Dist. Codes A-1 20         </div>			
14. SUBJECT TERMS		15. NUMBER OF PAGES 3	
		16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT UNCLASSIFIED	18. SECURITY CLASSIFICATION OF THIS PAGE UNCLASSIFIED	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT

## SHORT COMMUNICATION

# Quinolone Therapy of *Klebsiella pneumoniae* Sepsis following Irradiation: Comparison of Pefloxacin, Ciprofloxacin, and Ofloxacin

ITZHAK BROOK,<sup>1</sup> THOMAS B. ELLIOTT, AND G. DAVID LEDNEY

Wound Infection Management Program, Experimental Hematology Department, Armed Forces  
 Radiobiology Research Institute, Bethesda, Maryland 20814-5145

BROOK, I., ELLIOTT, T. B., AND LEDNEY, G. D. Quinolone Therapy of *Klebsiella pneumoniae* Sepsis following Irradiation: Comparison of Pefloxacin, Ciprofloxacin, and Ofloxacin. *Radiat. Res.* 122, 215-217 (1990).

Exposure to whole-body irradiation is associated with fatal gram-negative sepsis. The effect of oral therapy with three quinolones, pefloxacin, ciprofloxacin, and ofloxacin, for orally acquired *Klebsiella pneumoniae* infection was tested in B6D2F1 mice exposed to 8.0 Gy whole-body irradiation from bilaterally positioned <sup>60</sup>Co sources. A dose of 10<sup>8</sup> organisms was given orally 2 days after irradiation, and therapy was started 1 day later. Quinolones reduced colonization of the ileum with *K. pneumoniae*: 16 of 28 (57%) untreated mice harbored the organisms, compared to only 12 of 90 (13%) mice treated with quinolones ( $P < 0.005$ ). *K. pneumoniae* was isolated from the livers of 6 of 28 untreated mice, compared to only 1 of 90 treated mice ( $P < 0.001$ ). Only 5 of 20 (25%) untreated mice survived for at least 30 days compared with 17 of 20 (85%) mice treated with ofloxacin, 15 of 20 (75%) mice treated with pefloxacin, and 14 of 20 (70%) treated with ciprofloxacin ( $P < 0.05$ ). These data illustrate the efficacy of quinolones for oral therapy of orally acquired *K. pneumoniae* infection in irradiated hosts. © 1990

Academic Press, Inc.

## INTRODUCTION

Ionizing radiation reduces the host's defenses to infection (1) and enhances its susceptibility to systemic infection due to endogenous and exogenous organisms (2, 3). *Klebsiella pneumoniae* is one of the most frequent causes of gram-negative bacteremia (4, 5) and is especially prevalent in immunocompromised patients (6).

Therapy for severe systemic infection due to gram-negative bacteria generally involves the use of aminoglycosides in combination with  $\beta$ -lactam antibiotics (7). However, several recently developed quinolone compounds have exhibited high *in vitro* bactericidal activity against most gram-negative bacteria, including *K. pneumoniae* (8).

<sup>1</sup> To whom reprint requests should be addressed.

In this study, we evaluated the efficacy of oral therapy with several quinolones in a model of experimental septicemia due to orally ingested *K. pneumoniae* in irradiated mice.

## MATERIALS AND METHODS

## Animals

Female B6D2F1 mice approximately 10 weeks of age were obtained from Jackson Laboratories (Bar Harbor, ME). All animals were kept in quarantine for about 2 weeks before being transferred to a room with a 12-h light-dark cycle. Representative samples were examined to ensure the absence of specific bacteria and common murine diseases. Animals were maintained at an AAALAC accredited facility in microisolator cages on hardwood chip bedding and provided commercial rodent chow and acidified water (pH 2.2) that was changed to tap water 48 h before irradiation. All experimental procedures were done in compliance with National Institute of Health and Armed Forces Radiobiology Research Institute (AFRRI) guidelines regarding animal use and care.

## Cobalt-60 Irradiation

Mice were placed in Plexiglas restrainers and exposed to 8.0 Gy whole-body irradiation at 0.4 Gy/min from bilaterally positioned <sup>60</sup>Co sources. Dose determinations were made using a 50-ml AFRRI-designed tissue-equivalent ionization chamber calibrated against a National Institute of Standards and Technology ionization chamber. The dose within the exposure field varied by 3%, as determined by thermal luminescence dosimetry conducted within tissue-equivalent mouse phantoms.

## Bacteria

The strain used in this study was a clinical isolate of *K. pneumoniae* with a capsule type 5 (AFRRI No. 7). We have used this strain in previous animal studies (9). The organisms were harvested in the logarithmic phase of growth in brain heart infusion (BHI) media. A concentration of 10<sup>8</sup> organisms per 1 ml saline was prepared, and a volume of 0.1 ml was fed to each animal by gavage using a blunt syringe. This number of organisms was used since ingestion of lower number of bacteria did not produce a high mortality rate in the animals.

## Antimicrobials

Pefloxacin (Rhone-Poulenc-Sante, Anthony Cedex, France), ciprofloxacin (Miles Inc., West Haven, CT), and ofloxacin (Ortho Pharmaceutical Corp., Raritan, NJ) were obtained from their manufacturers. Standard powder formulations with known potencies were used for *in vitro* and *in vivo* studies. Pefloxacin and ciprofloxacin (25 mg/kg) were administered

20030207D11

01 E 05 155

every 12 h in 0.1 ml of water by gavage. In the case of ofloxacin 40 mg/kg was given once every day.

#### Antimicrobial Serum Concentration

Serum concentrations of the antimicrobials were measured in six mice 1 and 11 h after oral administration of pefloxacin and ciprofloxacin and 1 and 23 h after oral administration of ofloxacin on the fifth day of therapy. *Bacillus subtilis* ATCC 6633 was used as a test organism, and Mueller-Hinton agar (pH 7.4) was used as a test agar.

#### In Vitro Susceptibility

Minimal inhibitory concentrations and minimal bactericidal concentrations were determined in Mueller-Hinton broth that was inoculated with an inoculum of  $1.5 \times 10^5$  organisms per milliliter from an overnight culture. The values for minimal inhibitory concentration/minimal bactericidal concentration for *K. pneumoniae* used in this study were as follows: pefloxacin, 0.06/0.06 µg/ml; ciprofloxacin, 0.03/0.03 µg/ml; and ofloxacin, 0.06/0.12 µg/ml.

#### Microbial Methods

Animals challenged with bacteria were observed for mortality and signs of disease for 30 days. Five animals were selected at random for each group on Days 4, 6, 8, 10, and 12 following irradiation. Cultures were also obtained from another group of mice whenever the animals showed signs of serious illness and were moribund. Animals were killed by cervical dislocation. Specimens of livers were processed for microbial cultures. No other organs were processed and no blood samples were obtained, since previous studies showed that liver cultures correlated best with the presence of sepsis (3). The livers were removed aseptically and homogenized immediately. The ileum was opened, and ileal content samples were obtained using a swab. The liver and stool specimens were swabbed onto blood and MacConkey agars, and the organisms were identified using conventional methods (10).

#### Experimental Design

Forty-eight hours following irradiation, each mouse was fed  $10^8$  organisms. This time of feeding was chosen after preliminary data indicated that the animals became susceptible to *K. pneumoniae* sepsis when they were fed gram-negative bacteria 48 h after irradiation (Brook, Elliott, Ledney, unpublished data). The increased susceptibility to sepsis as a result of oral feeding 48 h after irradiation with gram-negative bacteria is similar to what we observed with *Pseudomonas aeruginosa* (11). Antimicrobial therapy was initiated 24 h later and was administered for 7 days. A total of 240 mice were included in each of the experiments, and each experiment was done three times. However, since the microbiological and mortality data were consistent, only the data from one experiment are reported. Each experiment was composed of the three antibiotic therapy groups and the untreated control group. Each therapy or control group consisted of 60 mice; 20 were observed for mortality, 30 were used for cultures of liver on the designated days, and 10 were used for cultures of livers of moribund animals.

#### Statistical Methods

Statistical analyses were done using the Cox-Mantel Test (12).

## RESULTS

#### Mortality

Mortality in the groups that received each of the quinolones was significantly less ( $P < 0.05$ ) than that of the untreated mice, but the groups were not different from each




FIG. 1. Survival of  $\gamma$ -irradiated mice B6D2F1 (8.0 Gy) fed  $10^8$  *K. pneumoniae* and treated orally with three quinolones. The data shown are from one experiment. Two repeated experiments yielded similar results.

other (Fig. 1). Only 25% of the untreated mice survived, compared with 85% of those treated with ofloxacin, 75% of those treated with pefloxacin, and 70% of those treated with ciprofloxacin.

#### Isolation of Organisms in Liver

*Klebsiella pneumoniae* was isolated in 6 of the 28 (21%) randomly selected untreated animals. There was no correlation between the time following irradiation and the isolation of *K. pneumoniae*. *Klebsiella pneumoniae* was recovered in only 1 of 30 (3%) animals treated with pefloxacin and in none of those treated with ciprofloxacin or ofloxacin ( $P < 0.05$ ). However, *K. pneumoniae* was recovered from 95% of moribund animals of all therapy or control groups.

#### Isolation of Organisms in Ileal Contents

*Klebsiella pneumoniae* was isolated in ileal content specimens of 16 of 28 (57%) untreated mice, compared to only 12 of 90 (13%) treated with quinolones ( $P < 0.005$ ). The rate of isolation of *K. pneumoniae* in quinolone-treated mice was 4 of 30 (13%) mice treated with pefloxacin, 5 of 30 (17%) mice treated with ciprofloxacin, and 3 of 30 (10%) mice treated with ofloxacin ( $P < 0.005$ ).

#### Antibiotic Serum Concentration

Mean serum concentrations of pefloxacin were as follows:  $2.4 (\pm 0.3 \mu\text{g/ml})$  at 1 h and  $0.2 (\pm 0.1 \mu\text{g/ml})$  at 11 h after administration of the antimicrobial. Mean concentrations of ciprofloxacin were  $2.8 (\pm 0.5 \mu\text{g/ml})$  at 1 h and  $0.2 (\pm 0.1 \mu\text{g/ml})$  at 11 h. Mean concentrations of ofloxacin were  $2.6 (\pm 0.4 \mu\text{g/ml})$  at 1 h and  $0.4 (\pm 0.2 \mu\text{g/ml})$  at 23 h.

## DISCUSSION

This study demonstrates that the three quinolones, pefloxacin, ciprofloxacin, and ofloxacin, can reduce the col-

onization of the ileum and the development of subsequent septicemia with *K. pneumoniae* in irradiated mice. It supports the findings of Trautmann *et al.* (13), who observed the efficacy of ciprofloxacin in the management of systemic *K. pneumoniae* infection in neutropenic mice.

We have developed a model of acquired *K. pneumoniae* infection in irradiated mice that may represent the mode of acquisition of external pathogens into an irradiated host. We have previously shown that irradiated animals develop fatal septicemia due to orally administered *P. aeruginosa* (11). We have also observed that the number of the endogenous aerobic and anaerobic bacteria in the gastrointestinal tract declined 24 h following irradiation and the decline was maximal at 7 days (14). The decrease in the number of that endogenous bacterial flora may make the host more susceptible to the acquisition of external pathogens such as *K. pneumoniae*.

The ability of *K. pneumoniae* to cause systemic infection in irradiated mice may be due to the following factors: the bacterial void created in the gut following the decline in the number of other organisms, the increased permeability of the mucosal cells damaged by irradiation, and the decrease in the local and systemic immune defenses.

The effectiveness of quinolones in the therapy of *K. pneumoniae* infection may be attributed to their local inhibition of the organism's growth within the gut lumen, while preserving the anaerobic gut flora (15), and to their systemic antibacterial activity against the organisms that spread to other body sites. The duration of quinolone therapy is yet to be determined. Although minimal mortality occurred following termination of therapy at Day 11, longer therapy might have prevented the mortality noticed after that day. Further studies are underway to determine the optimal duration of therapy.

Selective decontamination of the gut with orally administered quinolones is used to prevent sepsis in immunocompromised hosts (15, 16). These agents were also found to be effective in the management of septic episodes in neutropenic patients.<sup>2</sup> The availability of an oral route of administration, the advantage of achieving selective inhibition of potential pathogens in the gut, and the ability to treat systemic infection make the quinolones promising agents for the therapy of irradiated hosts.

#### ACKNOWLEDGMENTS

The authors acknowledge the secretarial assistance of Mrs. Gloria Contreras. This research was supported by the Armed Forces Radiobiology Research Institute, Defense Nuclear Agency, under work unit 4440-00129. Views presented in this paper are those of the authors; no endorsement by the Defense Nuclear Agency has been given or should be inferred.

<sup>2</sup> S. Segeve, S. D. Pitlick, and E. Reubenstein. Pefloxacin for gram negative infections in compromised patients. Abstract, 15th International Congress of Chemotherapy, Istanbul, Turkey, 1987.

Research was conducted according to the principles enunciated in the "Guide of the Care and Use of Laboratory Animals" prepared by the Institute of Animal Resources, National Research Council.

RECEIVED: June 2, 1989; ACCEPTED: November 28, 1989

#### REFERENCES

1. G. MATHE. Total body irradiation injury: A review of the disorders of the blood and hematopoietic tissues and their therapy. In *Nuclear Hematology* (E. Eszrami, Ed.), pp. 275-338. Academic Press, New York, 1965.
2. H. W. KAPLAN, R. S. SPECK, and F. JAWETZ. Impairment of antimicrobial defenses following total body irradiation of mice. *J. Lab. Clin. Med.* 40, 682-691 (1985).
3. I. BROOK, T. J. MACVITTIE, and R. I. WALKER. Recovery of aerobic and anaerobic bacteria from irradiated mice. *Infect. Immun.* 46, 270-271 (1984).
4. D. G. MAKI. Nosocomial bacteremia. An epidemiologic overview. *Am. J. Med.* 70, 719-732 (1981).
5. M. P. WEINSTEIN, L. B. RELLER, J. R. MURPHY, and K. A. LICHTENSTEIN. The significance of positive blood cultures: A comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. *Rev. Infect. Dis.* 5, 35-53 (1983).
6. T. UMSAWADI, E. A. MIDDLEMAN, M. LUNA, and G. P. BODDY. Klebsiella bacteremia in cancer patients. *Am. J. Med. Sci.* 165, 473-482 (1973).
7. J. W. HATHORN, M. RUBIN, and P. A. PIZZO. Empiric antibiotic therapy in the febrile neutropenic cancer patient: Clinical efficacy and impact of monotherapy. *Antimicrob. Agents Chemother.* 31, 971-977 (1987).
8. M. P. WESTLAND and J. B. CORNETT. Quinolone antibacterial agents. *Annu. Rep. Med. Chem.* 20, 145-154 (1985).
9. G. S. MADONNA, G. D. LEDNEY, T. B. ELLIOTT, I. BROOK, J. I. ULRICH, K. P. MYERS, M. L. PATCHEN, and R. I. WALKER. Trehalose dimycolate enhances resistance to infection in neutropenic animals. *Infect. Immun.* 57, 2495-2501 (1989).
10. E. H. LENNETTE, A. BALOWS, W. HAUSLER, and J. H. SHADOMY, Eds. *Manual of Clinical Microbiology*, 4th ed. American Society for Microbiology, Washington, DC, 1985.
11. R. I. WALKER, I. BROOK, J. W. COSTERTON, T. J. MACVITTIE, and M. L. MYHAL. Possible association of mucous blanket integrity with post-irradiation colonization resistance. *Radiat. Res.* 104, 346-357 (1985).
12. T. E. LEE. *Statistical Methods for Survival Data Analysis*, pp. 127-129. Lifetime Learning Publications, Belmont, CA, 1980.
13. M. TRAUTMANN, O. BRUCKNER, R. MARRE, and H. HAHN. Comparative efficacy of ciprofloxacin, ceftizoxime, and gentamicin, given alone or in combination, in a model of experimental septicemia due to *Klebsiella pneumoniae* in neutropenic mice. *Infection* 16, 49-53 (1988).
14. I. BROOK, R. I. WALKER, and T. J. MACVITTIE. Effect of antimicrobial therapy on the gut flora and bacterial infection in irradiated mice. *Int. J. Radiat. Biol.* 53, 709-716 (1988).
15. S. PECQUET, A. ANDERMONT, and C. TANACREDE. Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. *Antimicrob. Agents Chemother.* 29, 1047-1052 (1986).
16. M. ROZENBERG-ARSKA, A. W. DEKKER, and J. VERHOEF. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment. The effect in fecal flora. *J. Infect. Dis.* 142, 104-107 (1985).